UROAV-81- methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate tablet

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV), SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU) (SODIUM CATION - UNII:LYR4M0NH37), PHENYL SALICYLATE (UNII: 28A37T47QO) (PHENYL SALICYLATE - UNII:28A37T47QO), METHYLENE BLUE (UNII: T42P99266K) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH), HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X)

Disponible depuis:

AvKARE

DCI (Dénomination commune internationale):

METHENAMINE

Composition:

METHENAMINE 81 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

 UroAv-81 Tablets is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. UroAv-81 Tablets is contraindicated in patients with a hypersensitivity to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).

Descriptif du produit:

UroAv-81 Tablets are blue speckled tablets imprinted with 210 on one side and plain on the other, available in bottles of 90 tablets, (NDC: 42291-851-90).

Statut de autorisation:

unapproved drug other

Résumé des caractéristiques du produit

UROAV-81- METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS, PHENYL
SALICYLATE,
METHYLENE BLUE AND HYOSCYAMINE SULFATE TABLET
AVKARE
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
UROAV-81 TABLETS
Rx Only
DESCRIPTION
UroAv-81 Tablets for oral administration.
Each tablet contains:
Methenamine 81 mg
Sodium Phosphate Monobasic 40.8 mg
Phenyl Salicylate 32.4 mg
Methylene Blue 10.8 mg
Hyoscyamine Sulfate 0.12 mg
Inactive ingredients: Lactose, Polyethylene Glycol, Crospovidone,
Magnesium Stearate, Colloidal
Silicon Dioxide, FD&C Blue # 1.
METHENAMINE. [100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1
] decane; hexamethylenetetramine;
HMT; HMTA; hexamine; 1,3,5,7-tetraazaadamantane hexamethylenemine;
Uritone; Urotropin. C
H
N
; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine
(hexamethylenetetramine) exists as
colorless, lustrous crystals or white crystalline powder. Its
solutions are alkaline to litmus. Freely
soluble in water, soluble in alcohol and in chloroform.
SODIUM PHOSPHATE MONOBASIC. [7558-80-7] Phosphoric acid sodium salt
(1:1); Sodium
biphosphate; sodium dihydrogen phosphate; acid sodium phosphate;
monosodium orthophosphate;
primary sodium phosphate; H
NaO
P; mol wt 119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%.
Monohydrate, white, odorless slightly deliquesce crystals or granules.
At 100° C loses all its water;
when ignited it converts to metaphosphate. It is freely soluble in
water and practically insoluble in
alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous
solution at 25° C: 4.5.
PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester;
Salol. C
H
O
; mol wt
214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus
oxy-chloride on a mixture
of phenol and salicylic acid. Phenyl Salicylate exists as white
crystals with a melting point of 41°-43°
C. It is very slightly soluble in water and freely soluble in alcohol.